Hidden Pitfalls in MET Exon 14 Testing
Large cohort study examines limitations of DNA- and RNA-based sequencing in routine diagnostics
Clinical Scorecard: Hidden Pitfalls in MET Exon 14 Testing
At a Glance
Category Detail
Condition Non-small cell lung cancer (NSCLC) Key Mechanisms Detection of MET exon 14 skipping variants as predictive biomarkers for targeted therapy Target Population Patients with NSCLC Care Setting Molecular testing laboratories
Key Highlights
MET exon 14 skipping alterations occur in approximately 3–4% of NSCLCs. Tissue testing shows high performance; liquid biopsy accuracy is lower. RNA testing confirmed exon 14 skipping in 107 out of 114 variants assessed. Two large deletions were missed by DNA-based testing but visible in raw data. Pass rates for liquid biopsy testing improved from 38% in 2022 to 63% in 2024. Guideline-Based Recommendations
Diagnosis
Assay validation should include large deletions, synonymous splice-site variants, and intronic changes. Management
Combine DNA- and RNA-based testing when sufficient material is available. Monitoring & Follow-up
Participate in external quality assessment programs to improve testing performance. Risks
False-negative results are common in liquid biopsy testing, especially for low allele fractions. Patient & Prescribing Data
Patients with NSCLC undergoing molecular testing for MET exon 14 alterations.
MET exon 14 skipping variants are established predictive biomarkers for targeted therapy.
Clinical Best Practices
Optimize liquid biopsy assays to improve detection rates. Validate bioinformatics pipelines alongside laboratory workflows. Related Resources & Content
